Munir T, Moreno C, Owen C, Follows G, et al. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. J Clin Oncol 2023;41:3689-3699.
PMID: 37279408